[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "SAVVY: Survival analysis for AdVerse events with VarYing follow-up times",
    "section": "",
    "text": "Contact\nReach out to Kaspar Rufibach with comments and suggestions.\n\n\nUpdates of this page\n\n24/11/2022: initial version online"
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "Regina Stegherr et al. (2021): Statistical analysis plan of the project, outlining all estimators and meta-analyses. arxiv | publication\nR. Stegherr, Schmoor, Lübbert, et al. (2021): Comparison of estimators via simulations. arxiv | publication\nR. Stegherr, Schmoor, Beyersmann, et al. (2021): Estimation of AE risk in one group. arxiv | publication\nRufibach et al. (2022): Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events. arxiv | publication\n\n\n\n\n\n\n\n\nReferences\n\nRufibach, Kaspar, Regina Stegherr, Claudia Schmoor, Valentine Jehl, Arthur Allignol, Annette Boeckenhoff, Cornelia Dunger-Baldauf, et al. 2022. “Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) – comparison of adverse event risks in randomized controlled trials.” Statistics in Biopharmaceutical Research, Accepted.\n\n\nStegherr, Regina, Jan Beyersmann, Valentine Jehl, Kaspar Rufibach, Friedhelm Leverkus, Claudia Schmoor, and Tim Friede. 2021. “Survival Analysis for AdVerse Events with VarYing Follow-up Times (SAVVY): Rationale and Statistical Concept of a Meta-Analytic Study.” Biometrical Journal 63 (March): 650–70.\n\n\nStegherr, R., C. Schmoor, J. Beyersmann, K. Rufibach, V. Jehl, A. Brückner, L. Eisele, et al. 2021. “Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.” Trials 22 (1): 420.\n\n\nStegherr, R., C. Schmoor, M. Lübbert, T. Friede, and J. Beyersmann. 2021. “Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events.” Pharmaceutical Statistics 20 (6): 1125–46."
  },
  {
    "objectID": "events.html",
    "href": "events.html",
    "title": "Events with contributions from the working group",
    "section": "",
    "text": "12th December 2022: Together with ASA NJ chapter the WG is co-organizing a webinar ASA New Jersey Chapter Webinar Series: Getting the question right: Applying the Estimand and Target Trial Frameworks with External Controls.\n29th-31st March 2023: Jonathan Siegel will give a presentation on estimands for time-to-event endpoints at the Duke Industry Statistics Symposium 2023."
  },
  {
    "objectID": "events.html#duke-industry-statistics-symposium",
    "href": "events.html#duke-industry-statistics-symposium",
    "title": "Events with contributions from the working group",
    "section": "29.03.2023: Duke Industry Statistics Symposium",
    "text": "29.03.2023: Duke Industry Statistics Symposium\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n29.03.2023\n\nUSA\nPresentation\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJonathan Siegel: NA"
  },
  {
    "objectID": "events.html#dia-china-webinar",
    "href": "events.html#dia-china-webinar",
    "title": "Events with contributions from the working group",
    "section": "21.10.2022: DIA China webinar",
    "text": "21.10.2022: DIA China webinar\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.10.2022\n\nChina\nPresentation\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJiajun Xu: Conditional and Marginal Treatment Effects in Clinical Trials"
  },
  {
    "objectID": "events.html#isoqol-2022",
    "href": "events.html#isoqol-2022",
    "title": "Events with contributions from the working group",
    "section": "19.10.2022: ISOQoL 2022",
    "text": "19.10.2022: ISOQoL 2022\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n19.10.2022\nPrague\nCzech Republic\nWorkshop\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nRachael Lawrance: NA"
  },
  {
    "objectID": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop",
    "href": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop",
    "title": "Events with contributions from the working group",
    "section": "20.09.2022: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop",
    "text": "20.09.2022: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n20.09.2022\nMaryland\nUSA\nContributed topic session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nDalong Huang (FDA): Adjusting for covariates in randomized trials: draft guidance and some examples\n\n\nHong Tian (Beigene): Conditional and Unconditional Treatment Effects in Clinical Trials\n\n\nDalong Patrick Huang: Adjusting for Covariates in Randomized Clinical Trials\n\n\nJonathan Siegel: Special interest group “Estimands in oncology”, sponsored by PSI and EFSPI\n\n\nSun et al: Estimands in Oncology: A Topical Panel Discussion"
  },
  {
    "objectID": "events.html#efspi-regulatory-statistics-workshop",
    "href": "events.html#efspi-regulatory-statistics-workshop",
    "title": "Events with contributions from the working group",
    "section": "14.09.2022: EFSPI Regulatory Statistics Workshop",
    "text": "14.09.2022: EFSPI Regulatory Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n14.09.2022\nBasel\nSwitzerland\nPoster\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nStefan Englert: NA"
  },
  {
    "objectID": "events.html#th-international-conference-on-multiple-comparison-procedures",
    "href": "events.html#th-international-conference-on-multiple-comparison-procedures",
    "title": "Events with contributions from the working group",
    "section": "30.08.2022: 12th International Conference on Multiple Comparison Procedures",
    "text": "30.08.2022: 12th International Conference on Multiple Comparison Procedures\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n30.08.2022\nBremen\nGermany\ntalk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nYi Liu: From Logic-respecting Efficacy Estimands to Logic-ensuring Analysis Principle in Randomized Clinical Trials with Subgroups"
  },
  {
    "objectID": "events.html#iscb-conference",
    "href": "events.html#iscb-conference",
    "title": "Events with contributions from the working group",
    "section": "21.08.2022: ISCB conference",
    "text": "21.08.2022: ISCB conference\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.08.2022\nNewcastle\nUK\nContributed talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Follow-up time in clinical trials with a time-to-event endpoint: Redefining the question(s)"
  },
  {
    "objectID": "events.html#joint-statistical-meetings",
    "href": "events.html#joint-statistical-meetings",
    "title": "Events with contributions from the working group",
    "section": "06.08.2022: Joint Statistical Meetings",
    "text": "06.08.2022: Joint Statistical Meetings\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n06.08.2022\nWashington\nUSA\npresentation in a TC session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nSiyoen Kil: Insights into couterfactual estimand, with application toward personalized medicine"
  },
  {
    "objectID": "events.html#dia-annual-meeting-in-china",
    "href": "events.html#dia-annual-meeting-in-china",
    "title": "Events with contributions from the working group",
    "section": "21.07.2022: DIA annual meeting in China",
    "text": "21.07.2022: DIA annual meeting in China\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.07.2022\nSuzhou\nChina\nPoster\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJiawei Wei: Special interest group “Estimands in oncology”, sponsored by PSI and EFSPI"
  },
  {
    "objectID": "events.html#icsa-international-chinese-statistical-association-applied-statistics-symposium",
    "href": "events.html#icsa-international-chinese-statistical-association-applied-statistics-symposium",
    "title": "Events with contributions from the working group",
    "section": "19.06.2022: ICSA (International Chinese Statistical Association) Applied Statistics Symposium",
    "text": "19.06.2022: ICSA (International Chinese Statistical Association) Applied Statistics Symposium\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n19.06.2022\nGainsville Florida\nUSA\npresentation\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nYue Shentu: From Logic-respecting Efficacy Estimands to Logic-ensuring Analysis Principle for Time-to-event Endpoint in Randomized Clinical Trials with Subgroups"
  },
  {
    "objectID": "events.html#psi-annual-conference",
    "href": "events.html#psi-annual-conference",
    "title": "Events with contributions from the working group",
    "section": "12.06.2022: PSI annual conference",
    "text": "12.06.2022: PSI annual conference\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n12.06.2022\nGothenburg\nSweden\nPoster and invited session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nStefan Englert (poster): Poster Special interest group “Estimands in oncology”, sponsored by PSI and EFSPI\n\n\nStefan Englert (intro talk): Introduction to the Estimands in OncologyWorking Group\n\n\nOliver Sailer: Duration of response and time to response into the estimand framework\n\n\nBjoern Bornkamp: Covariate adjust with binary and time to event endpoint and how to interpret marginal effect in oncology clinical trials\n\n\nStefan Englert (talk): Censoring and censoring mechanisms in light of the estimand framework\n\n\nRachael Lawrance: Estimands in Oncology Working Group PRO TaskForce"
  },
  {
    "objectID": "events.html#asa-biopharmaceutical-section",
    "href": "events.html#asa-biopharmaceutical-section",
    "title": "Events with contributions from the working group",
    "section": "26.05.2022: ASA Biopharmaceutical Section",
    "text": "26.05.2022: ASA Biopharmaceutical Section\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n26.05.2022\n\n\nwebinar\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nYi Liu: From Logic-respecting Efficacy Estimands to Logic-ensuring Analysis Principle in Randomized Clinical Trials with Subgroups"
  },
  {
    "objectID": "events.html#society-for-clinical-trials",
    "href": "events.html#society-for-clinical-trials",
    "title": "Events with contributions from the working group",
    "section": "15.05.2022: Society for Clinical Trials",
    "text": "15.05.2022: Society for Clinical Trials\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n15.05.2022\nSan Diego\nUSA\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nRachael Lawrance: The Estimand Framework from the ICH E9(R1) Statistical Principles for Clinical Trials Addendum: Current Implementation Status and Looking Forward\n\n\nGodwin Yung: Answering old questions with new tools: Application of the ICH E9 addendum in oncology"
  },
  {
    "objectID": "events.html#psi-journal-club-treatment-switching-in-clinical-trials",
    "href": "events.html#psi-journal-club-treatment-switching-in-clinical-trials",
    "title": "Events with contributions from the working group",
    "section": "26.04.2022: PSI Journal Club – Treatment Switching in Clinical Trials",
    "text": "26.04.2022: PSI Journal Club – Treatment Switching in Clinical Trials\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n26.04.2022\n\nUK\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJuliane Manitz: Estimands for Overall Survival in Clinical Trials with Treatment Switching in Oncology"
  },
  {
    "objectID": "events.html#isoqol-2021",
    "href": "events.html#isoqol-2021",
    "title": "Events with contributions from the working group",
    "section": "12.10.2021: ISOQoL 2021",
    "text": "12.10.2021: ISOQoL 2021\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n12.10.2021\n\n\nContributed talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKonstantina Skaltsa: An estimand perspective on the Mixed Model Repeated Measures (MMRM) for the analysis of longitudinal PRO data in clinical trials\n\n\nLibby Floden: Estimand Considerations for Time-to-Event Analysis of Patient-Reported-Outcomes"
  },
  {
    "objectID": "events.html#dia-webinar-estimands-how-and-why---a-real-life-case-study-in-oncology",
    "href": "events.html#dia-webinar-estimands-how-and-why---a-real-life-case-study-in-oncology",
    "title": "Events with contributions from the working group",
    "section": "28.09.2021: DIA webinar: Estimands How and Why - A Real Life Case Study in Oncology",
    "text": "28.09.2021: DIA webinar: Estimands How and Why - A Real Life Case Study in Oncology\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n28.09.2021\n\nUSA\nInvited training\n\n\n\n\nProgram\nno program available\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nStefan Englert: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nPaul Bycott: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nFeng Liu: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nJonathan Siegel: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nSammi Tang: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nJiawei Wei: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nLei Nie: Discussant from FDA (no slides)\n\n\nDonna Przepiorka: Discussant from FDA (no slides)"
  },
  {
    "objectID": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-1",
    "href": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-1",
    "title": "Events with contributions from the working group",
    "section": "21.09.2021: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop",
    "text": "21.09.2021: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.09.2021\n\nUSA\nInvited talks and panel discussion\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nDevan Mehrotra: Estimands and Sensitivity Analyses in Clinical Trials - Strengthening Alignment with ICH E9 (R1)\n\n\nKaspar Rufibach: Session organizer"
  },
  {
    "objectID": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-2",
    "href": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-2",
    "title": "Events with contributions from the working group",
    "section": "21.09.2021: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop",
    "text": "21.09.2021: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.09.2021\n\nUSA\nContributed topic session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJuliane Manitz: Estimands for Overall Survival in Clinical Trials with Treatment Switching in Oncology\n\n\nJonathan Siegel: Rethinking Censoring and Censoring Mechanisms in Light of the Estimands Framework\n\n\nSatrajit Roychoudhury: Estimand in Hematologic Oncology Trials\n\n\nYeh-Fong Chen: Discussant from FDA (no slides)\n\n\nQing Xu: Discussant from FDA (no slides)"
  },
  {
    "objectID": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-3",
    "href": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-3",
    "title": "Events with contributions from the working group",
    "section": "21.09.2021: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop",
    "text": "21.09.2021: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.09.2021\n\nUSA\nContributed topic session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nYi Liu: Correct and Logical Causal Inference in Randomized Controlled Trials with Biomarker Subgroups\n\n\nDong Xi: Conditional Estimands vs. Marginal Estimands: From Collapsibility to Logic Respect\n\n\nGene Anthony Pennello: Logical Causal Inference for the Odds Ratio and Hazard Ratio\n\n\nLei Nie: Discussant from FDA (no slides)"
  },
  {
    "objectID": "events.html#joint-statistical-meetings-1",
    "href": "events.html#joint-statistical-meetings-1",
    "title": "Events with contributions from the working group",
    "section": "08.08.2021: Joint Statistical Meetings",
    "text": "08.08.2021: Joint Statistical Meetings\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n08.08.2021\n\nUSA\nTopic contributed session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJianchang Lin: Utilizing Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect (no slides available)\n\n\nSteven Sun: Use of estimand Framework in Hematology Oncology Trials: Practical Implementation (no slides available)\n\n\nYi Liu: Logic-Respecting Efficacy Measures in the Presence of Prognostic or Predictive Biomarker Subgroups\n\n\nNatalia Kan-Dobrosky: Treatment Switching and estimands for Overall Survival in Oncology Clinical Trials: Issues and Controversies"
  },
  {
    "objectID": "events.html#psi-eiwg-webinar-estimands-in-oncology---how-and-why",
    "href": "events.html#psi-eiwg-webinar-estimands-in-oncology---how-and-why",
    "title": "Events with contributions from the working group",
    "section": "01.06.2021: PSI EIWG Webinar: Estimands in Oncology - How and Why",
    "text": "01.06.2021: PSI EIWG Webinar: Estimands in Oncology - How and Why\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n01.06.2021\n\nUK\nInvited training\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nStefan Englert: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nPaul Bycott: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nFeng Liu: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nJonathan Siegel: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nSammi Tang: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nJiawei Wei: Bringing estimands to lifelifethrough real case studies through real case studies\n\n\nAll: Recording of the entire event"
  },
  {
    "objectID": "events.html#society-for-clinical-trials-1",
    "href": "events.html#society-for-clinical-trials-1",
    "title": "Events with contributions from the working group",
    "section": "20.05.2021: Society for Clinical Trials",
    "text": "20.05.2021: Society for Clinical Trials\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n20.05.2021\n\nUSA\nTopic contributed session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nStefan Englert: How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies\n\n\nJonathan Siegel: How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies\n\n\nJuliane Manitz: How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies\n\n\nFeng Liu: How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies\n\n\nSteven Sun: How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies"
  },
  {
    "objectID": "events.html#duke-industry-statistics-symposium-1",
    "href": "events.html#duke-industry-statistics-symposium-1",
    "title": "Events with contributions from the working group",
    "section": "21.04.2021: Duke Industry Statistics Symposium",
    "text": "21.04.2021: Duke Industry Statistics Symposium\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.04.2021\n\nUSA\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nNatalia Kan-Dobrosky: Estimands in clinical trials with treatment switching"
  },
  {
    "objectID": "events.html#asa---fda---lungevity-symposium-statistical-considerations-in-oncology-clinical-trials-in-the-covid-19-era",
    "href": "events.html#asa---fda---lungevity-symposium-statistical-considerations-in-oncology-clinical-trials-in-the-covid-19-era",
    "title": "Events with contributions from the working group",
    "section": "11.02.2021: ASA - FDA - LUNGevity symposium: Statistical considerations in Oncology clinical trials in the COVID-19 era",
    "text": "11.02.2021: ASA - FDA - LUNGevity symposium: Statistical considerations in Oncology clinical trials in the COVID-19 era\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n11.02.2021\n\nUSA\nSymposium\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nEvgeny Degtyarev: How can the estimand framework support decentralized trials?\n\n\nKaspar Rufibach: How can the estimand framework support decentralized trials?"
  },
  {
    "objectID": "events.html#deming-conference-on-applied-statistics",
    "href": "events.html#deming-conference-on-applied-statistics",
    "title": "Events with contributions from the working group",
    "section": "09.12.2020: Deming Conference on Applied Statistics",
    "text": "09.12.2020: Deming Conference on Applied Statistics\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n09.12.2020\n\nUSA\nShortcourse\n\n\n\n\nProgram\nno program available\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nEvgeny Degtyarev: Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology\n\n\nKaspar Rufibach: Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology"
  },
  {
    "objectID": "events.html#working-group-pharmaceutical-industry-of-the-german-region-of-the-ibs-apf",
    "href": "events.html#working-group-pharmaceutical-industry-of-the-german-region-of-the-ibs-apf",
    "title": "Events with contributions from the working group",
    "section": "27.11.2020: Working group “Pharmaceutical Industry” of the German Region of the IBS (APF)",
    "text": "27.11.2020: Working group “Pharmaceutical Industry” of the German Region of the IBS (APF)\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n27.11.2020\n\nGermany\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nHannes Buchner: Estimands update: Summary of world-wide authority interaction\n\n\nKaspar Rufibach: Estimands update: Summary of world-wide authority interaction"
  },
  {
    "objectID": "events.html#the-effective-statistician-podcast-a-deep-dive-into-principal-stratification-and-causal-inference",
    "href": "events.html#the-effective-statistician-podcast-a-deep-dive-into-principal-stratification-and-causal-inference",
    "title": "Events with contributions from the working group",
    "section": "17.11.2020: The effective statistician podcast: A deep dive into principal stratification and causal inference",
    "text": "17.11.2020: The effective statistician podcast: A deep dive into principal stratification and causal inference\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n17.11.2020\n\nSwitzerland\nDiscussion\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Link to podcast\n\n\nBjoern Bornkamp: Link to podcast"
  },
  {
    "objectID": "events.html#joint-psi-efspi-asa-biop-webinar-estimands",
    "href": "events.html#joint-psi-efspi-asa-biop-webinar-estimands",
    "title": "Events with contributions from the working group",
    "section": "05.11.2020: Joint PSI, EFSPI & ASA BIOP Webinar: Estimands",
    "text": "05.11.2020: Joint PSI, EFSPI & ASA BIOP Webinar: Estimands\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n05.11.2020\n\nUK / USA\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nEvgeny Degtyarev: Estimand framework: What are the opportunities in oncology?"
  },
  {
    "objectID": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-4",
    "href": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-4",
    "title": "Events with contributions from the working group",
    "section": "22.09.2020: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop",
    "text": "22.09.2020: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n22.09.2020\n\nUSA\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJonathan Siegel: Industry Perspective on Subsequent Therapy: An Estimands Approach"
  },
  {
    "objectID": "events.html#webinar-of-the-basel-biometrics-section-rcts-meeting-causal-inference-principal-stratum-strategy-and-beyond",
    "href": "events.html#webinar-of-the-basel-biometrics-section-rcts-meeting-causal-inference-principal-stratum-strategy-and-beyond",
    "title": "Events with contributions from the working group",
    "section": "07.09.2020: Webinar of the Basel Biometrics Section: RCTs meeting causal inference: principal stratum strategy and beyond",
    "text": "07.09.2020: Webinar of the Basel Biometrics Section: RCTs meeting causal inference: principal stratum strategy and beyond\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n07.09.2020\n\nSwitzerland\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Introduction\n\n\nBjoern Bornkamp: Principal Stratum Strategy: Potential Role in Drug Development"
  },
  {
    "objectID": "events.html#gmds-cen-ibs-2020",
    "href": "events.html#gmds-cen-ibs-2020",
    "title": "Events with contributions from the working group",
    "section": "06.09.2020: GMDS & CEN IBS 2020",
    "text": "06.09.2020: GMDS & CEN IBS 2020\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n06.09.2020\nBerlin\nGermany\nContributed talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJuliane Manitz: Estimands for Overall Survival in \u000bclinical trials with treatment switching"
  },
  {
    "objectID": "events.html#joint-statistical-meetings-2",
    "href": "events.html#joint-statistical-meetings-2",
    "title": "Events with contributions from the working group",
    "section": "01.08.2020: Joint Statistical Meetings",
    "text": "01.08.2020: Joint Statistical Meetings\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n01.08.2020\nPhiladelphia\nUSA\nTopic contributed session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJonathan Siegel: Estimand Framework and Its Impact on Drug Development in Oncology\n\n\nAnja Schiel: Discussant (no slides)\n\n\nKunthel By: Discussant FDA (no slides)\n\n\nCatherine Njue: Discussant from Health Canada (no slides)\n\n\nRichard J. Cook: Discussant (no slides)"
  },
  {
    "objectID": "events.html#webinar-of-the-basel-biometrics-section-estimands-addendum-is-final-anything-new-for-oncology",
    "href": "events.html#webinar-of-the-basel-biometrics-section-estimands-addendum-is-final-anything-new-for-oncology",
    "title": "Events with contributions from the working group",
    "section": "29.06.2020: Webinar of the Basel Biometrics Section: Estimands addendum is final: Anything new for oncology?",
    "text": "29.06.2020: Webinar of the Basel Biometrics Section: Estimands addendum is final: Anything new for oncology?\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n29.06.2020\n\nSwitzerland\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Introduction\n\n\nAnja Schiel: Experiences with the estimand - the regulatory view\n\n\nRenaud Capdeville: Challenges and open questions in hematology: Estimand aspects in the RATIFY trial\n\n\nTina Nielsen: Challenges and open questions in hematology: Estimand aspects in the Gallium trial\n\n\nHannes Buchner & Ingolf Griebsch: Estimands in clinical trials with treatment switching\n\n\nStefan Englert: Commentary on previous talks taking COVID 19 into account\n\n\nAll: Recording of the entire event\n\n\nAll: Q&A document answering questions raised in chat during webinar"
  },
  {
    "objectID": "events.html#psi-conference-webinar-impact-of-covid-19-to-estimands",
    "href": "events.html#psi-conference-webinar-impact-of-covid-19-to-estimands",
    "title": "Events with contributions from the working group",
    "section": "11.06.2020: PSI Conference Webinar: Impact of COVID-19 to estimands",
    "text": "11.06.2020: PSI Conference Webinar: Impact of COVID-19 to estimands\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n11.06.2020\n\nUK\nInvited talk and panelist\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Application of the estimand framework to assess the impact of COVID-19 on clinical trials"
  },
  {
    "objectID": "events.html#estimands-in-oncology-virtual-panel-discussion-organized-by-cytel",
    "href": "events.html#estimands-in-oncology-virtual-panel-discussion-organized-by-cytel",
    "title": "Events with contributions from the working group",
    "section": "21.05.2020: Estimands in Oncology Virtual Panel Discussion (organized by Cytel)",
    "text": "21.05.2020: Estimands in Oncology Virtual Panel Discussion (organized by Cytel)\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n21.05.2020\n\nUSA\nInvited talk and panelist\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Estimands in oncology\n\n\nMichelle Casey: Discussant (no slides)"
  },
  {
    "objectID": "events.html#webinar-of-the-basel-biometrics-section-impact-of-covid-19-on-clinical-trials",
    "href": "events.html#webinar-of-the-basel-biometrics-section-impact-of-covid-19-on-clinical-trials",
    "title": "Events with contributions from the working group",
    "section": "06.05.2020: Webinar of the Basel Biometrics Section: Impact of COVID-19 on clinical trials",
    "text": "06.05.2020: Webinar of the Basel Biometrics Section: Impact of COVID-19 on clinical trials\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n06.05.2020\n\nSwitzerland\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nEvgeny Degtyarev: Short overview on COVID-19 from the Cross-Industry Oncology Estimands Working Group"
  },
  {
    "objectID": "events.html#isoqol",
    "href": "events.html#isoqol",
    "title": "Events with contributions from the working group",
    "section": "20.10.2019: ISOQoL",
    "text": "20.10.2019: ISOQoL\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n20.10.2019\nSan Diego\nUSA\nContributed talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nRachael Lawrance: Using PROs in clinical trials: what should I know about?"
  },
  {
    "objectID": "events.html#esmo",
    "href": "events.html#esmo",
    "title": "Events with contributions from the working group",
    "section": "27.09.2019: ESMO",
    "text": "27.09.2019: ESMO\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n27.09.2019\nBarcelona\nSpain\nPoster\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nDaniel George: Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)\n\n\nBryant Furlow: Commentary on poster"
  },
  {
    "objectID": "events.html#efspi-regulatory-statistics-workshop-1",
    "href": "events.html#efspi-regulatory-statistics-workshop-1",
    "title": "Events with contributions from the working group",
    "section": "23.09.2019: EFSPI Regulatory Statistics Workshop",
    "text": "23.09.2019: EFSPI Regulatory Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n23.09.2019\nBasel\nSwitzerland\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nEvgeny Degtyarev: Estimand framework: opportunity to rethink some old (and new) problems in Oncology trials?"
  },
  {
    "objectID": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-5",
    "href": "events.html#asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-5",
    "title": "Events with contributions from the working group",
    "section": "23.09.2019: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop",
    "text": "23.09.2019: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n23.09.2019\nWashington\nUSA\nContributed talks (including FDA discussant)\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nFeng Liu: Causal Estimand and Principal Stratum, an Overview and Potential Applications in Oncology\n\n\nJiangxiu Zhou: Estimands for PFS2\n\n\nAlexei C. Ionan (FDA discussant): Estimand Framework in Oncology Drug Development: Challenges and Opportunities"
  },
  {
    "objectID": "events.html#joint-statistical-meetings-3",
    "href": "events.html#joint-statistical-meetings-3",
    "title": "Events with contributions from the working group",
    "section": "27.07.2019: Joint Statistical Meetings",
    "text": "27.07.2019: Joint Statistical Meetings\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n27.07.2019\nDenver\nUSA\nTopic contributed session\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nEvgeny Degtyarev: Estimand framework in Oncology drug development impact and opportunities\n\n\nJonathan Siegel: Importance of censoring mechanisms in selecting appropriate estimands\n\n\nSteven Sun: Sensitivity Analysis vs Supportive Analysis under Estimand Framework: A Case Study in Hematological Malignancies\n\n\nMichelle Casey: Estimand Framework - Are we asking the right questions? A case study in the solid tumor setting"
  },
  {
    "objectID": "events.html#iscb-conference-1",
    "href": "events.html#iscb-conference-1",
    "title": "Events with contributions from the working group",
    "section": "14.07.2019: ISCB conference",
    "text": "14.07.2019: ISCB conference\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n14.07.2019\nLeuven\nBelgium\nContributed talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nRui Tang: Estimands in the Presence of Treatment Switching"
  },
  {
    "objectID": "events.html#dia-annual-meeting",
    "href": "events.html#dia-annual-meeting",
    "title": "Events with contributions from the working group",
    "section": "23.06.2019: DIA Annual meeting",
    "text": "23.06.2019: DIA Annual meeting\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n23.06.2019\nSan Diego\nUSA\nContributed talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nYi Liu: Estimand Framework and its Impact on Oncology Drug Development: Findings From An Industry Wide Working Group"
  },
  {
    "objectID": "events.html#psi-annual-conference-1",
    "href": "events.html#psi-annual-conference-1",
    "title": "Events with contributions from the working group",
    "section": "02.06.2019: PSI annual conference",
    "text": "02.06.2019: PSI annual conference\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n02.06.2019\nLondon\nUK\nContributed talks\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Estimand framework in Oncology drug development – impact and opportunities\n\n\nBjoern Bornkamp: Estimation of Principal Stratum Effects, an Overview and Potential Applications in Oncology"
  },
  {
    "objectID": "events.html#lifetime-data-science-conference",
    "href": "events.html#lifetime-data-science-conference",
    "title": "Events with contributions from the working group",
    "section": "29.05.2019: Lifetime Data Science Conference",
    "text": "29.05.2019: Lifetime Data Science Conference\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n29.05.2019\nPittsburgh\nUSA\nContributed talks including EMA discussant\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nJonathan Siegel: Survival Design Strategies in an Estimands Framework\n\n\nShoubhik Mondal: Traditional sensitivity analyses in oncology clinical trials what questions are they answering?\n\n\nFeng Liu: Developing Estimands in Oncology Trials: Understand Scientific Questions of Interest\n\n\nAnja Schiel (EMA discussant): ICH E9(R1) Addendum Blessing or curse?"
  },
  {
    "objectID": "events.html#dagstat",
    "href": "events.html#dagstat",
    "title": "Events with contributions from the working group",
    "section": "18.03.2019: DAGStat",
    "text": "18.03.2019: DAGStat\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n18.03.2019\nMunich\nGermany\nContributed talks\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nKaspar Rufibach: Estimand framework in Oncology drug development – impact and opportunities\n\n\nBjoern Bornkamp: Estimation of Principal Stratum Effects, an Overview and Potential Applications in Oncology\n\n\nViktoriya Stalbovskaya: Estimands in the presence of treatment switching\n\n\nHans-Jochen Weber: Implementation of the ICH E9 addendum: RATIFY -A case study in hematology"
  },
  {
    "objectID": "events.html#hta-efspi-sig-1-day-event",
    "href": "events.html#hta-efspi-sig-1-day-event",
    "title": "Events with contributions from the working group",
    "section": "15.02.2019: HTA EFSPI SIG 1-day event",
    "text": "15.02.2019: HTA EFSPI SIG 1-day event\n\n\n\n\n\n\n\n\n\ndate\nCity\nCountry\nType\n\n\n\n\n15.02.2019\nBerlin\nGermany\nInvited talk\n\n\n\n\nProgram\nLink to Program\n\n\nTalks and/or recording\n\n\n\n\n\n\n\nSpeaker (available slidedecks are linked)\n\n\n\n\nEvgeny Degtyarev: Estimands in Oncology"
  },
  {
    "objectID": "code.html",
    "href": "code.html",
    "title": "SAVVY: estimation of AE probabilities",
    "section": "",
    "text": "The assessment of safety is an important aspect of the evaluation of new therapies in clinical trials, with analyses of adverse events being an essential part of this. Standard methods for the analysis of adverse events such as the incidence proportion, i.e. the number of patients with a specific adverse event out of all patients in the treatment groups, do not account for both varying follow-up times and competing risks. Alternative approaches such as the Aalen-Johansen estimator of the cumulative incidence function have been suggested. Theoretical arguments and numerical evaluations support the application of these more advanced methodology, but as yet there is to our knowledge only insufficient empirical evidence whether these methods would lead to different conclusions in safety evaluations. The Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) project strives to close this gap in evidence by conducting a meta-analytical study to assess the impact of the methodology on the conclusion of the safety assessment empirically. Three papers are currently under review summarizing the rationale and results of the project:\n\nRegina Stegherr et al. (2021): statistical analysis plan, presenting the rationale and statistical concept of the empirical study conducted as part of the SAVVY project. The statistical methods are presented in unified notation and examples of their implementation in R and SAS are provided.\nR. Stegherr et al. (2021): 1-sample case, compares estimators of AE probabilities in one treatment arm,\nRufibach et al. (2022): 2-sample case, compares relative risk estimators comparing two treatment arms based on (1) AE probabilities and (2) hazards."
  },
  {
    "objectID": "code.html#packages",
    "href": "code.html#packages",
    "title": "SAVVY: estimation of AE probabilities",
    "section": "Packages",
    "text": "Packages\n\n# --------------------------------------------------------------\n# packages\n# --------------------------------------------------------------\npacks <- c(\"data.table\", \"etm\", \"survival\", \"mvna\", \"knitr\")    \nfor (i in 1:length(packs)){library(packs[i], character.only = TRUE)}"
  },
  {
    "objectID": "code.html#functions",
    "href": "code.html#functions",
    "title": "SAVVY: estimation of AE probabilities",
    "section": "Functions",
    "text": "Functions\nBelow all functions are defined.\n\ndata_generation_constant_cens: This function generates the dataset denoted by \\(S1\\) in Table~4 of (stegherr_20estimating?), i.e. we assume constant hazards for the AE hazard, the hazard for the competing event of death, and the hazard for the “soft” competing events. Censoring is uniform.\nincidenceProportion: Compute incidence proportion.\nprobTransIncidenceDensity: Compute probability transform incidence density ignoring competing events.\nprobTransIncidenceDensity: Compute probability transform incidence density ignoring competing events.\noneMinusKaplanMeier: Compute 1 - Kaplan-Meier estimator.\nAJE: Compute Aalen-Johansen estimator.\n\nThe argument CE codifies the type of competing event: CE = 2 refers to a competing event of death only whereas CE = 3 refers to all competing events.\n\n# --------------------------------------------------------------\n# functions\n# --------------------------------------------------------------\n\n# function to generate dataset with constant hazards for AE, death, and soft competing events\ndata_generation_constant_cens <- function(N, min.cens, max.cens, haz.AE, haz.death,\n                                          haz.soft, seed = 57 * i + 5){\n  \n  # status, 1 for AE, 2 for death 3 for soft competing event\n  set.seed(seed)\n  haz.all <- haz.AE + haz.death + haz.soft\n\n  my.data <- data.table(time_to_event = rep(0, N), type_of_event = rep(0, N))\n  my.data$time_to_event<- rexp(n = N, rate = haz.all) # event time\n  my.data$type_of_event <- rbinom(n = N, size = 2, \n                                  prob = c(haz.AE / haz.all, haz.death / haz.all, haz.soft / haz.all)) + 1\n                                  # status, 1 for AE, 2 for death 3 for soft competing event\n  my.data$cens <- runif(n = N, min = min.cens, max = max.cens)\n  my.data$type_of_event <- as.numeric(my.data$time_to_event <= my.data$cens) * my.data$type_of_event\n  my.data$time_to_event <- pmin(my.data$time_to_event, my.data$cens)\n  my.data$id <- 1:N\n\n  # reorder columns\n  my.data <- my.data[, c(\"id\", \"time_to_event\", \"type_of_event\", \"cens\")]\n  return(my.data)\n}\n\n# compute incidence proportion\nincidenceProportion <- function(data, tau){\n\n  ae <- nrow(data[type_of_event == 1 & time_to_event <= tau]) / nrow(data)\n  ae_prob_var <- ae * (1 - ae) / nrow(data)\n\n  res <- c(\"ae_prob\" = ae, \"ae_prob_var\" = ae_prob_var)\n  return(res)\n}\n\n# compute probability transform incidence density\nprobTransIncidenceDensity <- function(data, tau){\n\n  time <- data$time_to_event\n  incidence.dens <- nrow(data[type_of_event == 1 & time_to_event <= tau]) / \n    sum(ifelse(time <= tau, time, tau))\n  ae <- 1 - exp(-incidence.dens * tau)\n\n  var_A_var <- nrow(data[type_of_event == 1 & time_to_event <= tau]) / \n    sum(ifelse(time <= tau, time, tau)) ^ 2\n  ae_var <- exp(-incidence.dens * tau) ^ 2 * var_A_var * tau ^ 2\n\n  res <- c(\"ae_prob\" = ae, \"ae_prob_var\" = ae_var)\n  return(res)\n}\n\n# compute probability transform incidence density accounting for CE\nprobTransIncidprobTransIncidenceDensityCompEvents <- function(data, CE, tau){\n  \n  data2 <- data[, type_of_event2 := ifelse(CE == 2 & data$type_of_event == 3, 0, \n                                           ifelse(CE == 3 & data$type_of_event == 3, 2, type_of_event))]\n  time2 <- ifelse(data2$time_to_event <= tau, data2$time_to_event, tau)\n  s2 <- sum(time2)\n  \n  id <- sum(dim(data2[type_of_event2 == 1 & time_to_event <= tau])[1]) / s2\n  id_ce <- sum(dim(data2[type_of_event2 == 2 & time_to_event <= tau])[1]) / s2\n  tmp <- id + id_ce\n  ett <- exp(-tau * tmp)\n\n  ae_prob <- id / tmp * (1 - exp(- tau*tmp))\n  ae_prob_var <- (((ett *      (id_ce * (1 / ett - 1) + tau * id * tmp)) / tmp ^ 2) ^ 2 * id / s2 + \n                  ((ett * id * (tau * tmp - 1 / ett + 1)) / tmp ^ 2) ^ 2 * id_ce / s2)\n\n  res <- c(\"ae_prob\" = ae_prob, \"ae_prob_var\" = ae_prob_var)\n  return(res)\n}\n\n# compute 1 - Kaplan-Meier\noneMinusKaplanMeier <- function(data, tau){\n\n  if(nrow(data[type_of_event == 1]) == 0){\n    ae_prob <- 0\n    ae_prob_var <- 0\n  }\n\n  if(nrow(data[type_of_event == 1]) > 0){\n    help <- data.frame(id = data$id)\n    help$from <- 0\n    help$to <- ifelse(data$type_of_event != 1, \"cens\", data$type_of_event)\n    help$time <-ifelse(data$time_to_event == 0, 0.001, data$time_to_event)\n\n    tra <- matrix(FALSE, 2, 2)\n    tra[1, 2] <- TRUE\n    state.names <-as.character(0:1)\n    etmmm <-etm(help, state.names, tra, \"cens\", s = 0)\n\n    ae_prob <- summary(etmmm)[[2]][sum(summary(etmmm)[[2]]$time <= tau),]$P\n    ae_prob_var <- summary(etmmm)[[2]][sum(summary(etmmm)[[2]]$time <= tau),]$var\n  }\n\n  res <- c(\"ae_prob\" = ae_prob, \"ae_prob_var\" = ae_prob_var)\n  return(res)\n}\n\n# compute Aalen-Johansen estimator\nAJE <- function(data, CE, tau){\n\n  data[, type_of_event2 := ifelse(CE == 2 & data$type_of_event == 3, 0, \n                                  ifelse(CE == 3 & data$type_of_event == 3, 2, type_of_event))]\n  time <- data$time_to_event\n  type2 <- data$type_of_event2\n  \n  # conditions\n  c1 <- nrow(data[type_of_event2 == 1])\n  c2 <- nrow(data[type_of_event2 == 2])\n  \n  if(c1 == 0){\n   ae_prob <- 0\n   ae_prob_var <- 0\n  }\n\n  if(c2 == 0){\n    ce_prob <- 0\n    ce_prob_var <- 0\n  }\n\n  # define auxiliary objects\n  help <- data.frame(id = data$id)\n  help$from <- 0\n  help$time <-ifelse(time == 0, 0.001, time)\n  tra <- matrix(FALSE, 2, 2)\n  tra[1, 2] <- TRUE\n  state.names <- as.character(0:1)\n  \n  if(c1 == 0 & c2 != 0){\n    help$to <- ifelse(type2 != 2, \"cens\", type2 - 1)\n    etmmm <- etm(help, state.names, tra, \"cens\", s = 0)\n    setmm <- summary(etmmm)[[2]]\n    ce_prob <- setmm[sum(setmm$time <= tau),]$P\n    ce_prob_var <- setmm[sum(setmm$time <= tau),]$var\n  }\n\n  if(c1 != 0 & c2 == 0){\n    help$to <- ifelse(type2 != 1, \"cens\", type2)\n    etmmm <- etm(help, state.names, tra, \"cens\", s = 0)\n    setmm <- summary(etmmm)[[2]]\n   \n    ae_prob <- setmm[sum(setmm$time <= tau),]$P\n    ae_prob_var <- setmm[sum(setmm$time <= tau),]$var\n  }\n\n  if(c1 != 0 & c2 != 0){\n    help$to <- ifelse(!(type2 %in% c(1, 2)),\"cens\", type2)\n\n    tra <- matrix(FALSE, 3, 3)\n    tra[1, 2:3] <- TRUE\n    state.names <- as.character(0:2)\n    etmmm <- etm(help, state.names, tra, \"cens\", s = 0)\n    setmm <- summary(etmmm)\n   \n    ae_prob <- setmm[[2]][sum(setmm[[2]]$time <= tau),]$P\n    ae_prob_var <- setmm[[2]][sum(setmm[[2]]$time <= tau),]$var\n\n    ce_prob <- setmm[[3]][sum(setmm[[3]]$time <= tau),]$P\n    ce_prob_var <- setmm[[3]][sum(setmm[[3]]$time <= tau),]$var\n  }\n\n  res_ae <- c(\"ae_prob\" = ae_prob, \"ae_prob_var\" = ae_prob_var)\n  res_ce <- c(\"ce_prob\" = ce_prob, \"ce_prob_var\" = ce_prob_var)\n  \n  res <- rbind(res_ae, res_ce)\n  return(res)\n}"
  }
]